List Title | APhA DrugInfoLine

Rheumatology

SORT BY: Most Recent Most Viewed

February 12, 2018

Perioperative timing of infliximab did not alter the risk of serious infection

READ

PREVIEW
The risk of serious infections within 30 days or 1 year after elective hip or knee surgery was similar in patients who stopped infliximab (Remicade—Janssen) within 2 to 4 weeks of surgery compared...
October 2, 2017

New guideline for perioperative management of antirheumatic drugs

READ

PREVIEW
The American College of Rheumatology (ACR) and the American Association of Hip and Knee Surgeons (AAHKS) released a new guideline on the perioperative management of antirheumatic medications in...
July 17, 2017

Updated recommendations for glucocorticoid-induced osteoporosis

READ

PREVIEW
The American College of Rheumatology (ACR) released updated recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis in adults, children, and special populations....
July 10, 2017

Pharmacogenetic testing for allopurinol hypersensitivity is beneficial in select groups

READ

PREVIEW
Testing for the human leukocyte antigen HLA-B*5801 allele before initiating allopurinol was found to be cost effective for black and Asian patients but not for white or Hispanic patients...
May 8, 2017

Updated guideline on management of low back pain

READ

PREVIEW
The American College of Physicians (ACP) released an updated guideline on management of low back pain that recommends nonpharmacologic therapies as initial treatment for acute and chronic pain. If...

Pages

Medication Monitor

RSS Follow Medication Monitor on Twitter Follow APhA Druginfoline on Twitter

2215 Constitution Avenue NW, Washington, DC 20037 Telephone 202-628-4410 Fax 202-783-2351

© 2013 American Pharmacists Association All Rights Reserved.

About the American
Pharmacists Association

The American Pharmacists Association (APhA) is the organization whose members are recognized in society as essential in all patient care settings for optimal medication use that improves health, wellness and quality of life. Through information, education and advocacy, APhA empowers its members to improve medication use and advance patient care.

About APhA DrugInfoLine

APhA DrugInfoLine (ISSN 2162-3015) is a weekly publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not neccessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that the information contained in APhA DrugInfoLine is accurate and current; however, they shall have no ability to any person or entity with regard to claims, losses, or damage caused or alleged to be caused, directly or indirectly by use of any information contained in the publication. All decisions about drug therapy must be based on independent judgement of the clinician.